← Back to home

MDS/MYELOPROLIFERATIVE NEOPLASM-UNCLASSIFIABLE (MDS/MPN-UNCLASSIFIABLE)

Clinical trials for MDS/MYELOPROLIFERATIVE NEOPLASM-UNCLASSIFIABLE (MDS/MPN-UNCLASSIFIABLE) explained in plain language.

Never miss a new study

Get alerted when new MDS/MYELOPROLIFERATIVE NEOPLASM-UNCLASSIFIABLE (MDS/MPN-UNCLASSIFIABLE) trials appear

Sign up with your email to follow new studies for MDS/MYELOPROLIFERATIVE NEOPLASM-UNCLASSIFIABLE (MDS/MPN-UNCLASSIFIABLE), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Not yet finished but already full! 1

New hope for tough blood cancers: drug added to transplant process

Disease control Ongoing

This study is testing the safety of adding a drug called venetoclax to the standard treatment given before a bone marrow transplant for people with high-risk blood cancers like AML and MDS. It also tests giving venetoclax with other drugs after the transplant to try to prevent th…

Matched conditions: MDS/MYELOPROLIFERATIVE NEOPLASM-UNCLASSIFIABLE (MDS/MPN-UNCLASSIFIABLE)

Phase: PHASE1 • Sponsor: Jacqueline Garcia, MD • Aim: Disease control

Last updated Mar 30, 2026 14:33 UTC

MDS/MYELOPROLIFERATIVE NEOPLASM-UNCLASSIFIABLE (MDS/MPN-UNCLASSIFIABLE)

Get alerted when new MDS/MYELOPROLIFERATIVE NEOPLASM-UNCLASSIFIABLE (MDS/MPN-UNCLASSIFIABLE) trials appear

New hope for tough blood cancers: drug added to transplant process